The point mutation γ2F77I changes the potency and efficacy of benzodiazepine site ligands in different GABAA receptor subtypes

European Journal of Pharmacology

Volumn 636, Issue 1-3, 2010, Pages 18-27

  Ramerstorfer, Joachim ^a   Furtmüller, Roman ^a   Vogel, Elisabeth ^a   Huck, Sigismund ^a   Sieghart, Werner ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

2F77I mutation; Benzodiazepine site ligands; Efficacy; GABAA receptors; Potency; Recombinant receptors

Indexed keywords

3 METHYL 6 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 TRIAZOLO[4,3 B]PYRIDAZINE; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA1; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA2; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA3; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA4; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA5; 4 AMINOBUTYRIC ACID A RECEPTOR ALPHA6; 4 AMINOBUTYRIC ACID A RECEPTOR BETA3; 4 AMINOBUTYRIC ACID A RECEPTOR GAMMA2; 4 ETHYL 6,7 DIMETHOXY BETA CARBOLINE 3 CARBOXYLIC ACID METHYL ESTER; ABECARNIL; AMINO ACID; BENZODIAZEPINE DERIVATIVE; BRETAZENIL; CHLORIDE; DIAZEPAM; ETHYL 7 METHOXY 11,12,13,13A TETRAHYDRO 9 OXO 9H IMIDAZO[1,5 A]PYRROLO[2,1 C] [1,4]BENZODIAZEPINE 1 CARBOXYLIC ACID; FLUMAZENIL; L 655708; LIGAND; N METHYL BETA CARBOLINE 3 CARBOXAMIDE; UNCLASSIFIED DRUG; ZOLPIDEM; ZOPICLONE;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; ELECTRODE; FEMALE; NONHUMAN; OOCYTE; POINT MUTATION; PRIORITY JOURNAL; VOLTAGE CLAMP; WILD TYPE; XENOPUS LAEVIS;

ANIMALS; BENZODIAZEPINES; BINDING SITES; CHLORIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INVERSE AGONISM; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; LIGANDS; MICE; POINT MUTATION; RATS; RECEPTORS, GABA-A;

EID: 77952675421     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2010.03.015     Document Type: Article

References (46)

1. Atack J.R. Anxioselective compounds acting at the GABA(A) receptor benzodiazepine binding site. Curr. Drug Targets 2003, 2:213-232.
2. Atack J.R., Bayley P.J., Seabrook G.R., Wafford K.A., McKernan R.M., Dawson G.R. L-655,708 enhances cognition in rats but is not proconvulsant at a dose selective for alpha5-containing GABAA receptors. Neuropharmacology 2006, 51:1023-1029.
3. Atack J.R., Maubach K.A., Wafford K.A., O'Connor D., Rodrigues A.D., Evans D.C., Tattersall F.D., Chambers M.S., MacLeod A.M., Eng W.S., Ryan C., Hostetler E., Sanabria S.M., Gibson R.E., Krause S., Burns H.D., Hargreaves R.J., Agrawal N.G., McKernan R.M., Murphy M.G., Gingrich K., Dawson G.R., Musson D.G., Petty K.J. In vitro and in vivo properties of 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-ylme thoxy)-pyrazolo[1,5-d]-[1,2,4]triazine (MRK-016), a GABAA receptor alpha5 subtype-selective inverse agonist. J. Pharmacol. Exp. Ther. 2009, 331:470-484.
4. Baburin I., Khom S., Timin E., Hohaus A., Sieghart W., Hering S. Estimating the efficiency of benzodiazepines on GABA(A) receptors comprising gamma1 or gamma2 subunits. Br. J. Pharmacol. 2008, 155:424-433.
5. Baumann S.W., Baur R., Sigel E. Individual properties of the two functional agonist sites in GABA(A) receptors. J. Neurosci. 2003, 23:11158-11166.
6. Baur R., Sigel E. Benzodiazepines affect channel opening of GABA A receptors induced by either agonist binding site. Mol. Pharmacol. 2005, 67:1005-1008.
7. Baur R., Sigel E. Replacement of histidine in position 105 in the alpha(5) subunit by cysteine stimulates zolpidem sensitivity of alpha(5)beta(2)gamma(2) GABA(A) receptors. J. Neurochem. 2007, 103:2556-2564.
8. A receptors drastically alter the affinity for ligands of the benzodiazepine binding site. J. Biol. Chem. 1997, 272:11799-11804.
9. A receptor γ2 subunit. Neuropharmacology 2004, 47:17-34.
10. Cope D.W., Halbsguth C., Karayannis T., Wulff P., Ferraguti F., Hoeger H., Leppa E., Linden A.M., Oberto A., Ogris W., Korpi E.R., Sieghart W., Somogyi P., Wisden W., Capogna M. Loss of zolpidem efficacy in the hippocampus of mice with the GABAA receptor gamma2 F77I point mutation. Eur. J. Neurosci. 2005, 21:3002-3016.
11. Dawson G.R., Maubach K.A., Collinson N., Cobain M., Everitt B.J., MacLeod A.M., Choudhury H.I., McDonald L.M., Pillai G., Rycroft W., Smith A.J., Sternfeld F., Tattersall F.D., Wafford K.A., Reynolds D.S., Seabrook G.R., Atack J.R. An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition. J. Pharmacol. Exp. Ther. 2006, 316:1335-1345.
12. Ebert V., Scholze P., Sieghart W. Extensive heterogeneity of recombinant gamma-aminobutyric acidA receptors expressed in alpha 4 beta 3 gamma 2-transfected human embryonic kidney 293 cells. Neuropharmacology 1996, 35:1323-1330.
13. A receptors: limits, insights, future developments. Neuroscience 2003, 119:933-943.
14. Farrant M., Nusser Z. Variations on an inhibitory theme: phasic and tonic activation of GABA(A) receptors. Nat. Rev. Neurosci. 2005, 6:215-229.
15. Fleck M.W. Molecular actions of (S)-desmethylzopiclone (SEP-174559), an anxiolytic metabolite of zopiclone. J. Pharmacol. Exp. Ther. 2002, 302:612-618.
16. Hadingham K.L., Garrett E.M., Wafford K.A., Bain C., Heavens R.P., Sirinathsinghji D.J., Whiting P.J. Cloning of cDNAs encoding the human gamma-aminobutyric acid type A receptor alpha 6 subunit and characterization of the pharmacology of alpha 6-containing receptors. Mol. Pharmacol. 1996, 49:253-259.
17. Hadley S.H., Amin J. Rat alpha6beta2delta GABAA receptors exhibit two distinct and separable agonist affinities. J. Physiol. 2007, 581:1001-1018.
18. A channel subtypes. Mol. Neurobiol. 1998, 18:35-86.
19. June H.L., Foster K.L., McKay P.F., Seyoum R., Woods J.E., Harvey S.C., Eiler W.J., Grey C., Carroll M.R., McCane S., Jones C.M., Yin W., Mason D., Cummings R., Garcia M., Ma C., Sarma P.V., Cook J.M., Skolnick P. The reinforcing properties of alcohol are mediated by GABA(A1) receptors in the ventral pallidum. Neuropsychopharmacology 2003, 28:2124-2137.
20. Knoflach F., Benke D., Wang Y., Scheurer L., Luddens H., Hamilton B.J., Carter D.B., Mohler H., Benson J.A. Pharmacological modulation of the diazepam-insensitive recombinant gamma-aminobutyric acidA receptors alpha 4 beta 2 gamma 2 and alpha 6 beta 2 gamma 2. Mol. Pharmacol. 1996, 50:1253-1261.
21. Leppa E., Vekovischeva O.Y., Linden A.M., Wulff P., Oberto A., Wisden W., Korpi E.R. Agonistic effects of the beta-carboline DMCM revealed in GABA(A) receptor gamma 2 subunit F77I point-mutated mice. Neuropharmacology 2005, 48:469-478.
22. Li X., Cao H., Zhang C., Furtmueller R., Fuchs K., Huck S., Sieghart W., Deschamps J., Cook J.M. Synthesis, in vitro affinity, and efficacy of a bis 8-ethynyl-4H-imidazo[1, 5a]-[1, 4]benzodiazepine analogue, the first bivalent alpha5 subtype selective BzR/GABA(A) antagonist. J. Med. Chem. 2003, 46:5567-5570.
23. Nutt D. Pharmacological and behavioural studies of benzodiazepine antagonists and contragonists. Adv. Biochem. Psychopharmacol. 1983, 38:153-173.
24. Ogris W., Poltl A., Hauer B., Ernst M., Oberto A., Wulff P., Hoger H., Wisden W., Sieghart W. Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA(A) receptor gamma2 subunit. Biochem. Pharmacol. 2004, 68:1621-1629.
25. Olsen R.W., Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 2008, 60:243-260.
26. Petroski R.E., Pomeroy J.E., Das R., Bowman H., Yang W., Chen A.P., Foster A.C. Indiplon is a high-affinity positive allosteric modulator with selectivity for alpha1 subunit-containing GABAA receptors. J. Pharmacol. Exp. Ther. 2006, 317:369-377.
27. - currents. Mol. Pharmacol. 1991, 39:691-696.
28. Puia G., Ducic I., Vicini S., Costa E. Molecular mechanisms of the partial allosteric modulatory effects of bretazenil at gamma-aminobutyric acid type A receptor. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:3620-3624.
29. 3H]L-655,708, a novel ligand selective for the benzodiazepine site of GABAA receptors which contain the α5 subunit. Neuropharmacology 1996, 35:1331-1335.
30. Rivas F.M., Stables J.P., Murphree L., Edwankar R.V., Edwankar C.R., Huang S., Jain H.D., Zhou H., Majumder S., Sankar S., Roth B.L., Ramerstorfer J., Furtmuller R., Sieghart W., Cook J.M. Antiseizure activity of novel gamma-aminobutyric acid (A) receptor subtype-selective benzodiazepine analogues in mice and rat models. J. Med. Chem. 2009, 52:1795-1798.
31. Sanna E., Busonero F., Talani G., Carta M., Massa F., Peis M., Maciocco E., Biggio G. Comparison of the effects of zaleplon, zolpidem, and triazolam at various GABA(A) receptor subtypes. Eur. J. Pharmacol. 2002, 451:103-110.
32. Savic M.M., Huang S., Furtmuller R., Clayton T., Huck S., Obradovic D.I., Ugresic N.D., Sieghart W., Bokonjic D.R., Cook J.M. Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?. Neuropsychopharmacology 2008, 33:332-339.
33. A receptor subtypes. Pharmacol. Rev. 1995, 47:181-234.
34. Sieghart W., Eichinger A., Riederer P., Jellinger K. Comparison of benzodiazepine receptor binding in membranes from human or rat brain. Neuropharmacology 1985, 24:751-759.
35. A receptors. Trends Pharmacol. Sci. 1997, 18:425-429.
36. Sigel E., Baur R., Trube G., Mohler H., Malherbe P. The effect of subunit composition of rat brain GABAA receptors on channel function. Neuron 1990, 5:703-711.
37. Skerritt J.H., Macdonald R.L. Benzodiazepine Ro 15-1788: electrophysiological evidence for partial agonist activity. Neurosci. Lett. 1983, 43:321-326.
38. Smith A.J., Alder L., Silk J., Adkins C., Fletcher A.E., Scales T., Kerby J., Marshall G., Wafford K.A., McKernan R.M., Atack J.R. Effect of alpha subunit on allosteric modulation of ion channel function in stably expressed human recombinant gamma-aminobutyric acid(A) receptors determined using (36)Cl ion flux. Mol. Pharmacol. 2001, 59:1108-1118.
39. Taylor S.C., Johnston A.L., Wilks L.J., Nicholass J.M., File S.E., Little H.J. Kindling with the beta-carboline FG7142 suggests separation between changes in seizure threshold and anxiety-related behaviour. Neuropsychobiology 1988, 19:195-201.
40. Vellucci S.V., Webster R.A. Is Ro15-1788 a partial agonist at benzodiazepine receptors?. Eur. J. Pharmacol. 1983, 90:263-268.
41. Wafford K.A., Bain C.J., Whiting P.J., Kemp J.A. Functional comparison of the role of gamma subunits in recombinant human gamma-aminobutyric acidA/benzodiazepine receptors. Mol. Pharmacol. 1993, 44:437-442.
42. Wafford K.A., Whiting P.J., Kemp J.A. Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant gamma-aminobutyric acidA receptor subtypes. Mol. Pharmacol. 1993, 43:240-244.
43. Walters R.J., Hadley S.H., Morris K.D., Amin J. Benzodiazepines act on GABAA receptors via two distinct and separable mechanisms. Nat. Neurosci. 2000, 3:1274-1281.
44. Whittemore E.R., Yang W., Drewe J.A., Woodward R.M. Pharmacology of the human gamma-aminobutyric acidA receptor alpha 4 subunit expressed in Xenopus laevis oocytes. Mol. Pharmacol. 1996, 50:1364-1375.
45. A receptor that determine ligand binding and modulation at the benzodiazepine site. Mol. Pharmacol. 1997, 52:874-881.
46. Wulff P., Goetz T., Leppa E., Linden A.M., Renzi M., Swinny J.D., Vekovischeva O.Y., Sieghart W., Somogyi P., Korpi E.R., Farrant M., Wisden W. From synapse to behavior: rapid modulation of defined neuronal types with engineered GABAA receptors. Nat. Neurosci. 2007, 10:923-929.